Convalescent plasma didn't prevent severe COVID-19 in high-risk patientsEarly use of convalescent plasma didn't prevent COVID-19 progression in a group of high-risk adult outpatients, concludes a National Institutes of Health (NIH) study yesterday in the New England Journal of Medicine (NEJM).The randomized, controlled Clinical Trial of COVID-19 Convalescent Plasma in Outpatients (C3PO) trial enrolled more than 500 participants who visited 1 of 48 US emergency departments within 7 days of COVID-19 symptom onset.
Enrollees were 50 and older and had one or more risk factors for severe COVID-19 (eg, obesity, high blood pressure, diabetes, heart disease, chronic lung disease).The participants were assigned to receive either one unit (250